XML 24 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Changes in Equity - USD ($)
$ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2019 $ 15,063 $ 56 $ 27,312 $ (6,956) $ (2,312) $ (4,128) $ 13,972 $ 1,091
Beginning balance, shares at Dec. 31, 2019   1,198,000,000            
Net income (loss) (4,099)     (3,990)     (3,990) (109)
Other comprehensive income (loss) (30)       (86)   (86) 56
Issuance of Treasury Shares 1           1  
Issuance of Shares, shares   4            
Stock-based compensation expense 129   129       129  
Transactions with non-controlling interests (2)             (2)
Ending balance at Dec. 31, 2020 11,061 $ 57 27,443 (10,946) (2,399) (4,128) 10,026 1,035
Ending balance, shares at Dec. 31, 2020   1,202,000,000            
Net income (loss) 456     417     417 39
Other comprehensive income (loss) (391)       (283)   (283) (107)
Issuance of Shares, shares   7,000,000            
Stock-based compensation expense 119   119       119  
Transactions with non-controlling interests (2)             (2)
Ending balance at Dec. 31, 2021 11,244 $ 57 27,561 (10,529) (2,683) (4,128) 10,278 966
Ending balance, shares at Dec. 31, 2021   1,209,000,000            
Net income (loss) (2,406)     (2,353)     (2,353) (53)
Other comprehensive income (loss) (270)       (154)   (154) (116)
Issuance of Shares, value 1   1       1  
Issuance of Shares, shares   8,000,000            
Stock-based compensation expense 124   124       124  
Transactions with non-controlling interests (2)             (2)
Ending balance at Dec. 31, 2022 $ 8,691 $ 57 $ 27,688 $ (12,882) $ (2,838) $ (4,128) $ 7,897 $ 794
Ending balance, shares at Dec. 31, 2022   1,217,000,000